- Walgreens Boots reported an adjusted earnings per share (EPS) of 38 cents, surpassing the estimate of 31 cents.
- The company’s total sales reached $38.99 billion, which was higher than the estimated $36.79 billion.
- U.S. Retail Pharmacy Sales were $30.72 billion, exceeding the forecast of $28.98 billion.
- U.S. Healthcare Sales amounted to $2.10 billion, aligning with the projected figure of $2.1 billion.
- International sales amounted to $6.2 billion, surpassing the anticipated $5.83 billion.
- Adjusted operating income came in at $558 million, which was above the expected $413.5 million.
- The company attributes the positive results to improvements in the U.S. Healthcare segment and benefits from cost savings initiatives, despite ongoing weaknesses in U.S. front-end sales.
- Analyst recommendations show 1 buy, 12 holds, and 1 sell.
Walgreens Boots Alliance on Smartkarma
On Smartkarma, independent analysts provide valuable insights into companies like Walgreens Boots Alliance. Behind the Money‘s recent research, “Retail’s last barbarian takes on Walgreens Boots,” highlights the challenges faced by the company in the past decade due to E-commerce competition. Sycamore Partners’ $24 billion leveraged buyout of Walgreens Boots marks their healthcare sector entry, a move that contrasts with major private equity firms’ caution in retail buyouts.
Conversely, Baptista Research sheds optimistic light on Walgreens Boots Alliance in their report, “Walgreens Boots Alliance: An Insight Into Its Procurement Optimization.” Despite mixed financial results, the company’s strategic realignments and focus on its U.S. Retail Pharmacy business show promise. With progress in store optimization and script retention rates post closures exceeding expectations, the company is actively working toward positive growth trajectories.
A look at Walgreens Boots Alliance Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking at the Smartkarma Smart Scores for Walgreens Boots Alliance, the company seems to have a positive long-term outlook. With high scores in Dividend and Value, investors may find Walgreens Boots Alliance an attractive option for income generation and potentially undervalued assets. However, the lower scores in Growth and Resilience indicate that the company may face challenges in terms of expanding its business and handling unexpected market disruptions. The Momentum score of 4 suggests that there may be positive price trends in the near future.
Walgreens Boots Alliance, Inc., is a retail drugstore operator offering a wide range of prescription and non-prescription medications along with general merchandise. The company provides various health services focusing on primary and acute care, wellness, pharmacy services, disease management, and health and fitness. With its strong emphasis on both healthcare and retail, Walgreens Boots Alliance aims to cater to diverse customer needs while navigating the complex dynamics of the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
